Page 33 - Test PDF v5

« Back to Contents ENDOMETRIAL CANCER

LiFE re

Literature for ENYGO

Emerging molecular targets in endometrial cancer

Editor Ines Vasconcelos In the second article Papa et al. reviewed and highlighted the main
angiogenetic molecular pathways and the anti-angiogenic agents in
Descriptive summary phase II clinical trials for EC treatment.

In this last quarter there was yet another disappointing trial on
temsirolimus in endometrial cancer (EC). This phase II clinical trial
evaluated temsirolimus—a mTOR inhibitor—and included 22 pa-
tients with advanced or recurrent EC. These women were no longer
amenable to curative surgery and/or radiotherapy and had had no
previous or only adjuvant chemotherapy. Patients received weekly
IV infusions of 25 mg temsirolimus. After eight weeks of treatment,
8 of 20 evaluable patients had progressive disease, thus failing to
meet the predefined trial efficacy criteria. This study is also cited in
“Medical treatment of recurrent ovarian cancer“ by K. Zalewski.

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract
Gynecol Oncol.
1 Temsirolimus in women with platinum-refractory/resistant ovarian cancer or Emons G et al. http://www.ncbi.nlm.nih.gov/
advanced/recurrent endometrial carcinoma. A phase II study of the AGO-stu- pubmed/26731724
dy group (AGO-GYN8).

2 Targeting angiogenesis in endometrial cancer - new agents for tailored Papa A et al. Expert Opin Investig Drugs. http://www.ncbi.nlm.nih.gov/
treatments. pubmed/26560489

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 33